Slide 1: Orion Half-Year Financial Report January–June 2024
Orion Half-Year Financial Report January–June 2024 8 August 2024
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements which involve risks and uncertainty factors. These statements are not based on historical facts but relate to the Company’s future activities and performance. They include statements about future strategies and anticipated benefits of
Slide 3: Q2 2024 – Both net sales and operating profit showed strong growth
Q2 2024 – Both net sales and operating profit showed strong growth • The growth in net sales was driven by Nubeqa® and 4–6/ 4–6/ Animal Health business division 2024 2023 Change • The growth in operating profit was due to growing sales and especially growing Nubeqa® royalties • Solid growth even wit
Slide 4: January–June 2024 results
January–June 2024 results • All business units performed well 1–6/ 1–6/ Change • Nubeqa®, Easyhaler® and Animal Health business 2024 2023 division were the growth drivers of net sales • The growth in operating profit was due to growing Net sales, EUR million 636.7 567.5 +12.2% sales and especially g
Slide 5: Net sales bridge from H1’2023 to H1’2024
Net sales bridge from H1’2023 to H1’2024 1 Simdax® and dexmedetomidine for human use 5 Other products and services (excl. Animal Health and Fermion) 2 Nubeqa® (product sales and royalty) 6 Animal Health and Fermion 3 Entacapone products 7 Milestones 4 Easyhaler® product portfolio 8 Exchange rates 5
Slide 6: Operating profit bridge from H1’2023 to H1’2024
Operating profit bridge from H1’2023 to H1’2024 1 Product & service sales without sales margin and product mix change and exchange rate effect 5 Milestones 2 Product sales margin and product mix change but without exchange rate effect 6 Other operating income and expenses 3 Exchange rate effect on g
Slide 7: Innovative Medicines EUR 137.5 million (+46.0%)
Innovative Medicines EUR 137.5 million (+46.0%) • Nubeqa® sales booked by Orion were EUR 121.1 Nubeqa® sales booked by Orion1 million (+45.9%) 80 • The remainder of the business division’s net sales 70 was mainly product sales for research purposes 60 • Orion has pricing and reimbursement processes
Slide 8: Branded Products EUR 141.2 million (+11.3%)
Branded Products EUR 141.2 million (+11.3%) 90 • Easyhaler® product portfolio 81.2 Sales split 80 (+19.0)% continued strong 4% growth 68.2 70 • Other products performed as 60 8% expected 50 46.8 MEUR 43.2 • Orion signed a license 40 agreement for Precifit® 30 (Flexilev®) to strengthen 31% 57% Parkin
Slide 9: Generics and Consumer Health EUR 257.2 million (-1.2%)
Generics and Consumer Health EUR 257.2 million (-1.2%) 250 • Excluding Simdax®, Sales split by geographic dexmedetomidine products for areas human use and Russia1, net sales 195.1 192.8 200 development was positive → underlying business was solid 13% 150 • Simdax® and dexmedetomidine MEUR 10% produc
Slide 10: Animal Health and Fermion
Animal Health and Fermion • Animal Health growth (+22.8%) Animal Health Fermion came from various sources with 70 70 61.8 animal sedatives being the single 60 60 largest contributor 50.3 50 18.8 50 12.8 38.5 40 40 37.3 MEUR 30 30 20 43.0 20 37.5 10 10 0 0 1–6/2023 1–6/2024 1–6/2023 1–6/2024 Sedative
Slide 11: TOP 10 products and total sales split by division
TOP 10 products and total sales split by division EUR vs. Product or product portfolio million 1–6/2023 Sales split in 1–6/2024 1. Nubeqa® 121.1 +45.9% 2. Easyhaler® product portfolio 81.2 +19.0% 3. Entacapone products1 43.2 -7.7% 6% 10% 22% 4. Dexdomitor®, Domitor®, Domosedan®, Antisedan® 18.8 +46.
Slide 12: News flow after H1 2024
News flow after H1 2024 12 8 August 2024 © Orion Corporation
Slide 13: Option exercise with MSD and ARANOTE topline in July
Option exercise with MSD and ARANOTE topline in July Exercise of option providing MSD/Merck global Phase III ARANOTE trial with darolutamide meets exclusive rights to opevesostat primary endpoint FINANCIAL TERMS • Significantly increasing radiological progression-free Upfront payment USD 290 million
Slide 14: Key clinical development pipeline
Key clinical development pipeline Project/compound Indication PHASE I PHASE II PHASE III REGISTRATION ARANOTE / darolutamide 1 Prostate cancer (mHSPC) Completed ARASTEP / darolutamide 1 Prostate cancer (BCR) Ongoing OMAHA1 / opevesostat 2 Prostate cancer (mCRPC) Ongoing OMAHA2a / opevesostat 2 Prost
Slide 15: Orion recognized for developing sustainability and transparency in vast supply chain of 6,000 suppliers
Orion recognized for developing sustainability and transparency in vast supply chain of 6,000 Key actions in 2024 suppliers across 60 countries. This is crucial to… Integration to • … ensure compliance with increasing regulatory scenario planning and requirements and supply chain resilience risk man
Slide 16: Outlook for 2024 (updated on 1 July 2024)
Outlook for 2024 (updated on 1 July 2024) Net sales EUR 1,440–1,480 million Operating EUR 350–380 million profit 16 8 August 2024 © Orion Corporation
Slide 17: Upcoming events
Upcoming events Interim Report 1–9/2024 29/10/2024 Financial Statement Release for 2024 25/2/2025 AGM 2025 planned to be held 3/4/2025 Interim Report 1–3/2025 23/4/2025 Half-Year Financial Report 1–6/2025 18/7/2025 Interim Report 1–9/2025 28/10/2025 18 8 August 2024 © Orion Corporation